Effect of food or proton pump inhibitor treatment on the bioavailability of dacomitinib in healthy volunteers
Authors:
- 9 October 2015
- journal article
- research article
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 56 (2) , 223-230
Abstract
This phase 1, open‐label crossover study evaluated the relative bioavailability of dacomitinib in healthy volunteers under fed and fasted conditions and following coadministration with rabeprazole, a potent acid‐reducing proton pump inhibitor (PPI). Twenty‐four male subjects received a single dacomitinib 45‐mg dose under 3 different conditions separated by washout periods of ≥16 days: coadministered with rabeprazole 40 mg under fasting conditions; alone under fasting conditions; and alone after a high‐fat, high‐calorie meal. Increased peak exposure of 23.7% (90% confidence interval [CI], 5.3%–45.2%) was detected with dacomitinib taken after food versus fasting. The adjusted geometric mean ratio (fed/fasted) for area under the plasma concentration−time curve from time zero to infinity (AUCinf) was 114.2% (90%CI, 104.7%–124.5%) and not considered clinically meaningful. In the fasted state, a decrease in dacomitinib AUCinf was observed following rabeprazole versus dacomitinib alone (PPI+fasted/fasted alone): 71.1% (90%CI, 61.7%–81.8%). Dacomitinib was generally well tolerated. Dacomitinib may be taken with or without food. Use of long‐acting acid‐reducing agents, such as PPIs with dacomitinib should be avoided if possible. Shorter‐acting agents such as antacids and H2‐receptor antagonists may have lesser impact on dacomitinib exposure and may be preferable to PPIs if acid reduction is clinically required.Keywords
Funding Information
- Pfizer
This publication has 20 references indexed in Scilit:
- Pharmacokinetics and Pharmacodynamics of the Proton Pump InhibitorsJournal of Neurogastroenterology and Motility, 2013
- Phase I and pharmacokinetic study of dacomitinib (PF-00299804), an oral irreversible, small molecule inhibitor of human epidermal growth factor receptor-1, -2, and -4 tyrosine kinases, in Japanese patients with advanced solid tumorsInvestigational New Drugs, 2012
- Phase I Dose-Escalation Study of the Pan-HER Inhibitor, PF299804, in Patients with Advanced Malignant Solid TumorsClinical Cancer Research, 2011
- Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitorMolecular Cancer Therapeutics, 2008
- PF00299804, an Irreversible Pan-ERBB Inhibitor, Is Effective in Lung Cancer Models withEGFRandERBB2Mutations that Are Resistant to GefitinibCancer Research, 2007
- Erlotinib in Previously Treated Non–Small-Cell Lung CancerNew England Journal of Medicine, 2005
- Dietary Effects on Drug Metabolism and TransportClinical Pharmacokinetics, 2003
- Food-Drug InteractionsDrugs, 2002
- Effects of Food on Clinical PharmacokineticsClinical Pharmacokinetics, 1999
- Antacids RevisitedDrugs, 1999